Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. - Wikidata - wikimedia - TriplyDB

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy.

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy.

http://www.wikidata.org/entity/Q37124256

about

Current trends in management of hepatitis B virus reactivation in the biologic therapy era Hepatitis B: the virus and disease Association between hepatitis B virus and pancreatic cancer Prevention of Hepatitis B reactivation in the setting of immunosuppression KASL clinical practice guidelines: management of chronic hepatitis B Hepatitis B and Hepatitis C Reactivation in the Biologic Era Hepatitis B virus reactivation with rituximab-containing regimen Management of patients with hepatitis B who require immunosuppressive therapy Acute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis B Cancer and liver cirrhosis: implications on prognosis and management Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy Treatment of rheumatic diseases and hepatitis B virus coinfection Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis.Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression.Prevention of hepatitis B virus reactivation under rituximab therapy.Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.HBV-Associated Acute Liver Failure After Immunosuppression and Risk of Death.Hepatitis C virus screening in patients with cancer receiving chemotherapy.Bortezomib induced hepatitis B reactivation.Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?Evaluation of the patient with hepatitis B Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study.Recent advances in managing hepatitis B.Hepatitis B virus management to prevent reactivation after chemotherapy: a review.Chemotherapy-related reactivation of hepatitis B infection: updates in 2013.Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports HBV reactivation in an occult HBV infection patient treated with prednisone for nephrotic syndrome: case report and literature review.Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists.Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center.The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma.Case report: passive transfer of hepatitis B antibodies from intravenous immunoglobulin.Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening.Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure.Hepatitis B reactivation and rituximab in the oncology practice.When treating cancer, please don't forget hepatitis B.

P2860

Q24634879-E3C47DD0-DB75-48C4-AD8E-410302790592 Q24642704-92066481-268F-466E-B76B-6B58608F3841 Q24656650-619DF325-8674-405D-AFBB-51B97BA97E69 Q26747023-F46F9D1B-B96E-44E2-A9E6-49021E6B575F Q26752475-E5D4E916-6B3F-4D66-BCD0-9C8D587C18B4 Q26781993-684EA429-2F2F-47CA-A58F-A6695A7465B2 Q26830484-84050533-9003-40CB-8933-B009244850B2 Q26853490-8D8CEE3B-F2EF-496B-8106-17735613A581 Q27022622-726B715D-641E-4DF7-8C5F-2B2E4DE12D95 Q28068579-97F6FC8D-E00E-4071-8F1E-A21769B47E74 Q28070090-815E36B5-7E08-4279-9F6C-A9F96BDA6124 Q28084305-76BA93E9-8DAB-4B65-A6A4-80D7281C15EF Q30248818-87414EA3-414E-4128-9479-72628E7F577B Q30391932-31F379D7-CE74-47D6-9950-B74A713F1F68 Q30434625-FC1AADF5-4602-4529-938A-59FE1217A2F9 Q33390799-27AC9D31-C2D3-4657-A0D8-AD4B2668A267 Q33414243-99A7EDD0-A7B4-4108-9A04-C46D2613E7CB Q33433133-EE8A458E-245D-40C4-B8AB-02615316A5E5 Q33600085-A36BEC2B-99A4-43F8-A122-B4C143127B8B Q33615071-045DEC58-7812-4F52-A2CB-CF53E16ABB57 Q33742856-1E26D02D-3A8C-46A6-BFCF-2BF947ACA7AC Q33872389-CFDC7C95-4FDD-446E-A632-4EBA14FED08D Q33896660-6454E710-4F70-4ED5-A862-19E0409621E1 Q34106504-F09FAFD2-5BE5-4AC1-B5E1-4F40C528BE6A Q34167574-8DF5C403-9A66-4D22-99AE-C3DAEE106F4D Q34397738-F2D4C85F-AC65-42B8-9999-AE7A62B7147F Q34404991-2E8BF27D-15F2-4E58-9F7F-A065C8E03B71 Q34854165-21905217-27A9-475D-AE04-5FE25D0AF507 Q34974369-1CFD9957-0C88-418E-86D5-6C5770CD80B1 Q34974883-B78C74FB-01AC-478D-8B73-DD81F2E1A5E0 Q35037621-0EDD2DE7-F136-4D1B-B342-06C3FEA70710 Q35057889-9CAAB4ED-2332-49ED-9AA8-FCFB4E933A9F Q35095916-8105E814-F513-4C63-8654-8C612F264A55 Q35100218-3A56BF14-9ADD-42CD-A2E3-76E46D9D80D3 Q35375654-EC1CC107-2D14-496C-8D9D-894BD7E50F59 Q35429416-8C0B3577-9196-4734-A693-83E5C434F276 Q35535861-A8FF5AE0-4A0F-4CCE-B9B7-920B99E1C78C Q35567748-83FB5418-1611-484F-8FDD-458EFD3D305E Q35583718-589CF125-5FB9-4595-BB3D-4DB58B694388 Q35584210-B1E922E4-A48B-4808-B87F-01A59B74B811

P2860

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy.

http://www.wikidata.org/entity/Q37124256

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Systematic review: the effect ...... ctivation during chemotherapy.

@en

Systematic review: the effect ...... ctivation during chemotherapy.

@nl

type

label

Systematic review: the effect ...... ctivation during chemotherapy.

@en

Systematic review: the effect ...... ctivation during chemotherapy.

@nl

prefLabel

Systematic review: the effect ...... ctivation during chemotherapy.

@en

Systematic review: the effect ...... ctivation during chemotherapy.

@nl

P1433

Q37124256-92D44C54-B73E-4B82-9AA3-0FEB092ECE29

P1476

Q37124256-79BB030C-A922-4AE2-96EC-180159F075F3

P2093

Q37124256-1B6C09B5-EB31-4717-8744-C95EC32B0124

Q37124256-235DA43A-0CEE-48DB-83FF-E8F332BEBE1A

Q37124256-8D146EBD-253F-4B16-AFF1-6BE01A6AB0FA

Q37124256-A5AEEEA7-AE93-4AE7-8E93-15A7C68CBD6C

Q37124256-A9EB258E-9422-4AA4-AE9B-452491AAA88C

Q37124256-D58D909B-70C1-4BC9-B3C1-D665D183B9F5

Q37124256-F3FDFDDE-3B56-4E32-B545-3AD16771676D

P2860

Q37124256-053ACF3F-3458-4B9C-B6D5-B61A51B23738

Q37124256-05EF13D6-B20D-49DA-8357-422BA89F3B97

Q37124256-0611C0AC-6CBA-4AD7-8C92-0A4F5348867A

Q37124256-090AB760-C9FE-4BF9-AE8A-2233CA266E0A

Q37124256-096DA0CE-BE00-4B70-AA5D-7F6CF4433FF1

Q37124256-09A3E07F-A138-4FA0-9F8A-FF2426D5E9A2

Q37124256-1A059211-042C-4CFC-BDF4-894A74EA5FF5

Q37124256-1D259B7D-B275-479B-8526-DC116EE0DBEE

Q37124256-2D5BA040-06EF-4273-9462-BA32CE19B649

Q37124256-2FCAE9C5-8886-45D5-9A70-994E3466DFDE

P304

Q37124256-A47EBF9D-E303-4120-B6C5-998ADDD417F4

P31

Q37124256-F62AB257-B4E1-4B21-A81F-FC61C5638A04

P356

Q37124256-771A9A0C-73ED-496A-AF4B-F9F0E3EEA0CF

P407

Q37124256-468AAD5B-1F8F-4A7D-8648-014A7AE50A9F

P433

Q37124256-1A8BD6E5-53DF-4223-BC55-AB89D5D90133

P478

Q37124256-1C24EF30-ACB6-4878-B7D9-A45A8C8AA143

P577

Q37124256-24983FEB-2CB9-49DE-980B-C1D9C82065B8

P698

Q37124256-29AD63DD-4A07-4170-8473-FB36851E7610

P921

Q37124256-AFBFA3F5-0E5A-4263-9FBB-8D9E26AAB3C1

P932

Q37124256-7764514C-915D-4643-9B87-C80AC2A18CEB

P356

0003-4819-148-7-200804010-00008

P1433

Annals of Internal Medicine

P1476

Systematic review: the effect ...... ctivation during chemotherapy.

@en

P2093

Ayana Rowley

http://www.w3.org/2001/XMLSchema#string

Frank Pucino

http://www.w3.org/2001/XMLSchema#string

Gyorgy Csako

http://www.w3.org/2001/XMLSchema#string

Jay H Hoofnagle

http://www.w3.org/2001/XMLSchema#string

Robert Wesley

http://www.w3.org/2001/XMLSchema#string

Rohit Loomba

http://www.w3.org/2001/XMLSchema#string

T Jake Liang

http://www.w3.org/2001/XMLSchema#string

P2860

Hepatitis B virus infection--natural history and clinical consequences

Chronic hepatitis B.

The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy

Hepatitis B surface antigen prevalence among pregnant women in urban areas: implications for testing, reporting, and preventing perinatal transmission.

Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with hemato-oncological neoplasias treated with chemotherapy.

Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis

Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version).

Epidemiology of hepatitis B in Europe and worldwide.

Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.

P304

519-528

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7326/0003-4819-148-7-200804010-00008

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

148

http://www.w3.org/2001/XMLSchema#string

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18378948

http://www.w3.org/2001/XMLSchema#string

P921

P932

2729097

http://www.w3.org/2001/XMLSchema#string